Safety and Efficacy of Eculizumab in Patients with Refractory Myasthenia Gravis
There was a rapid and sustained clinical response in patients treated with eculizumab for anti-acetylcholine receptor-positive refractory generalized myasthenia gravis.
Myasthenia Gravis
Solifenacin Succinate LS Approved for Neurogenic Detrusor Overactivity
The FDA has approved solifenacin succinate LS oral suspension for the treatment of neurogenic detrusor overactivity in pediatric patients 2 years of age and older.
Guidance for Management of Myasthenia Gravis and Lambert-Eaton Myasthenic Syndrome During COVID-19
The International Myasthenia Gravis/COVID-19 Working Group has published a short guidance statement on the management of MG and Lambert-Eaton myasthenic syndrome during this novel pandemic.
The Clinical Effect of Zilucoplan in Patients With Generalized Myasthenia Gravis
Zilucoplan yielded rapid, clinically meaningful, and sustained improvement in patients with moderate to severe generalized myasthenia gravis.
Zilucoplan for Myasthenia Gravis Gets Orphan Drug Designation
The Food and Drug Administration has granted Orphan Drug designation to zilucoplan for the treatment of generalized myasthenia gravis and other rare, tissue-based complement-mediated diseases.
Long-Term Benefits of Eculizumab Examined in Generalized Myasthenia Gravis
Alexion announced the publication of data from the phase 3 open-label extension of the REGAIN trial (ECU-MG-302) that assessed the long-term safety and efficacy of eculizumab (Soliris) for the treatment of adults with anti-acetylcholine receptor (AChR) antibody-positive refractory generalized myasthenia gravis (gMG).
Thymectomy + PDN Beneficial for Non-Thymomatous Myasthenia Gravis
For patients with non-thymomatous myasthenia gravis, thymectomy plus prednisone confers benefits versus prednisone alone at 5 years.
Belimumab Nonsuperior to Placebo for Reducing Symptoms of Myasthenia Gravis
The investigators suggest that the recruited participants may have reached a plateau in symptoms, which may have decreased the chances of additional improvement with belimumab treatment.
Firdapse NDA Submitted for Lambert-Eaton Myasthenic Syndrome
Results from the Phase 3 trial showed that the Quantitative Myasthenia Gravis (QMG) score at baseline to day 14 changed from 6.4 to 6.7 in the amifampridine group vs. 5.6 to 7.9 for the placebo group.
Myasthenia Gravis Impairment Index Indicates Response to Prednisone, IVIg, PLEX
The Myasthenia Gravis Impairment Index was developed to incorporate patient input at different stages of disease progression.
-
Loading...
-
Loading...
Next post in Neuromuscular Disorders
